Tag Archives: atrial fibrillation patient populations

Boehringer Ingelheim to unveil new data on the novel oral anticoagulant (NOAC) Pradaxa® (dabigatran etexilate) during the ESC Congress 2013 in Amsterdam

For media outside of the US, the UK & Canada only Ingelheim, Germany, 26-8-2013 — /EuropaWire/ — Boehringer Ingelheim today announced the upcoming presentation of new data on the novel oral anticoagulant (NOAC) Pradaxa® (dabigatran etexilate) during the ESC Congress 2013 organised … Read the full press release